s.sadeghi@caropharmed.com
Razi Vaccine and Serum Research Institute
Writing Module 4 (Preclinical) and Module 5 (Clinical) of the Vaccine
Karayakhteh Tajhiz Azma Company
Writing Module 4 of the CAR-T Cell Product
Artiman Pharmed Alborz Company
Initial Design of the Clinical Study for the Surfactant Product
Aram Pishdad Aras Azma Company
Phase 3 Clinical Study of the Wart Over Drug
Persis Gen Par Company
Design and Execution of Phase 3 Clinical Study for the Perkinra Drug
Participation in Writing the Clinical Study Article for the Perkinra Drug
Writing Module 5 of the Perkinra Drug for Export
Padra Serum Alborz Company
Writing PBRER for the ScoFab Product
Writing PBRER for the SnaFab Product
Writing RMP for the SnaFab Product
Writing the Pharmacovigilance System Master File (PSMF)
Nivad Pharmed Salamat Company
Design and Implementation of Phase 3 Clinical Trial for FluGuard Vaccine
Design of Phase 3 Clinical Trial for PapilloGuard 4 Vaccine
Design of Phase 3 Clinical Trial for FluGuard Vaccine in Individuals Aged 9 to 18
Design of Phase 3 Clinical Trial for 13-Valent PneumoConj Vaccine
Initial Design of Clinical Trial for Rotavirus Vaccine
Writing of Phase 3 and Phase 3 Extension Clinical Trial Article for FluGuard Vaccine
Writing of PBRER for FluGuard Vaccine
Vira Cell Company
Writing the Final Report of the Clinical Study for the Product
Noyan Pejouhan Zist Darou Company
Writing the PBRER for the 2-Valent PapilloGuard
Homa Pharmed Pharmaceutical Company
Participation in the Design of Bioequivalence Study
Dorsa Darou Pharmaceutical Company
Writing Module 4 (Preclinical) and Module 5 (Clinical) of the Product
Padra Serum Alborz Company
Writing the PBRER for ScoFab Product
Writing the PBRER for SnaFab Product
Karayakhteh Tajhiz Azma Company
Design and Implementation of Clinical Study for CAR T Cell Product
Safety and Efficacy Evaluation of PerkinRA in Comparison with Kineret in Systemic Juvenile Idiopathic Arthritis Patients
A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID‐19
Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18–60 years: A double-blind, non-inferiority, randomized controlled trial
Immunogenicity and safety evaluation of a newly manufactured recombinant Baculovirus-Expressed quadrivalent influenza vaccine in adults 18 years old and Above: An Open-Label, phase III extension study
Immunogenicity and safety of a bivalent, adjuvant system 04-adjuvanted human papillomavirhttps://pubmed.ncbi.nlm.nih.gov/35352698/us vaccine in healthy female volunteers aged 15-25: a randomized, double-blind, phase III, noninferiority clinical trial
caropharmed
info@caropharmed.com
